



Discontinuation of all Pegasys (peginterferon alfa-2a) and Pegasys RBV 135 mcg presentations

Roche Products (New Zealand) Ltd, the supplier of Pegasys, is alerting customers that all stock of the Pegasys 135 mcg and Pegasys RBV 135 mcg/112 presentations are now exhausted and will no longer be available.

Roche is still supplying the market with the Pegasys 180 mcg presentation in three different SKUs. Pegasys remains the only peginterferon alfa-2a with/without ribavirin funded (Sole Subsidised Supply) in the community until 30 June 2017.

A 135 mcg dose can still be delivered if required, as the 180 mcg PFS barrel is marked with a 135 mcg dose point. After removal of the needle cap, the patient can expel a portion of the dose as waste by depressing the plunger to the 135 mcg dose point. The patient can then self-inject with the remaining dose in the PFS.

Status	Product	Pharma code	Price*	HCL order no.
Subsidised	Pegasys PFS 180 mcg x 4	2162806	\$900.00	1130448
Subsidised	Pegasys RBV (180/112) Comb. Therapy Pack	2190117	\$1159.84	1125613
Subsidised	Pegasys RBV (180/168) Comb. Therapy Pack	2190087	\$1290.00	101125614

*Note: * A confidential rebate applies to all subsidised dispensing in the community.*

Please continue to place your Pegasys and Pegasys RBV orders via the Healthcare Logistics (HCL) electronic ordering system. Alternatively, wholesalers may call customer services at HCL on 0800 476 243 or 0800 762 433 (fax).

Kind regards,

David Roberts
Commercial Manager
Roche Products (New Zealand) Ltd